
ESOMATE-RD-40 CAPS
MRP: 2
Packaging: 10x10
Pack Type: tablet
Composition:
Esomeprazole Magnesium 40mg + Domperidone 30mg (SR)
Indication:
for the treatment of gastroesophageal reflux disease (GERD), acid reflux, dyspepsia, nausea, vomiting, and gastric motility disorders. It provides acid suppression and prokinetic action for effective relief from upper gastrointestinal symptoms.
Description:
Esomeprazole Magnesium 40 mg + Domperidone 30 mg (Sustained Release) is a powerful combination therapy for managing gastroesophageal reflux disease (GERD), acid reflux, dyspepsia, and nausea.
Esomeprazole is a proton pump inhibitor (PPI) that reduces stomach acid by inhibiting the H⁺/K⁺ ATPase enzyme in gastric parietal cells.
Domperidone SR is a prokinetic agent that enhances gastric motility and speeds up gastric emptying, relieving symptoms like nausea, bloating, and fullness.
This synergistic formula provides dual-action relief—acid suppression and motility regulation—with once-daily convenience, especially effective in acid reflux with delayed gastric emptying.
Tags:
- Dual-action relief: acid suppression + gastric motility enhancement
- Effective for GERD, nausea, fullness, and bloating
- Sustained-release Domperidone for longer-lasting prokinetic effect
- Reduces heartburn, regurgitation, and indigestion
- Once-daily dosing for convenience and compliance
- Supports faster gastric emptying and symptom resolution
Usage Information
Dosage
Adults: One capsule daily, 30–60 minutes before a meal (preferably breakfast) Do not crush or chew the capsule Duration: Typically 4 to 8 weeks or as directed by a healthcare provider Follow your doctor’s instructions for dose adjustments or extended use
Side Effects
Common: Headache, abdominal pain, constipation, dry mouth, nausea Less common: Dizziness, rash, flatulence Rare: QT prolongation (with high doses of Domperidone), hypomagnesemia, vitamin B12 deficiency Long-term use may require monitoring of electrolytes and renal function
Contraindications
Known hypersensitivity to Esomeprazole, Domperidone, or other PPIs Patients with QT prolongation or cardiac arrhythmias Severe hepatic or renal impairment Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) Avoid in children below 12 years unless specifically advised by a physician
